メインコンテンツへスキップ
見出し画像

IL-6 and the Acute-Phase Response: How the Liver Drives CRP Production (Part 1 of 3)

    Introduction

    Interleukin-6 (IL-6) is a pleiotropic cytokine involved in acute-phase and immune responses during inflammation, while also participating in tissue-protective and regenerative processes. One of its best-characterized systemic functions is the induction of acute-phase protein production in the liver, where inflammatory signaling is converted into a coordinated change in the composition of circulating proteins [Kishimoto, 2005; Rose-John, 2018; Hunter and Jones, 2015; Garbers et al., 2018; Tanaka et al., 2014].

    This hepatic response is often encountered clinically through C-reactive protein (CRP), but CRP is only one output of a broader biological program. IL-6 signaling through gp130 activates both the JAK–STAT3 and JAK–SHP-2–MAPK pathways, with STAT3 playing a central role in the transcriptional control of IL-6-responsive genes, including genes encoding acute-phase proteins [Hunter and Jones, 2015; Garbers et al., 2018; Tanaka et al., 2014].

    The key question is therefore not simply why CRP rises. It is how an inflammatory signal is received by hepatocytes, converted into a transcriptional program, and subsequently restrained by negative feedback. This article follows that sequence from the systemic acute-phase response to IL-6 receptor architecture, STAT3-dependent transcription, and SOCS3-mediated feedback.


    From Systemic Inflammation to a Hepatic Acute-Phase Program

    The acute-phase response is a systemic program

    The acute-phase response is triggered by inflammatory stimuli associated with infection, tissue injury, and related forms of biological stress. Although changes in hepatic protein synthesis are among its most visible manifestations, the response is not confined to the liver. It also encompasses broader behavioral, physiological, biochemical, nutritional, and metabolic changes [Gabay and Kushner, 1999; Steel and Whitehead, 1994].

    Within this systemic program, production of positive acute-phase proteins by hepatocytes increases. The resulting rise in circulating proteins such as CRP, serum amyloid A (SAA), and haptoglobin reflects a coordinated hepatic response rather than the induction of a single isolated marker [Gruys et al., 2005].

    Some positive acute-phase proteins participate directly in host defense. Depending on the protein, these functions include the capture or opsonization of microorganisms and their products and engagement of complement-associated mechanisms. More broadly, the acute-phase response contributes to antimicrobial defense and tissue repair during inflammation [Gruys et al., 2005; Mantovani and Garlanda, 2023].

    Why IL-6 is a major hepatic input

    IL-6 acts as a major inducer of acute-phase protein production in the liver, although it does not operate in isolation. IL-1 and tumor necrosis factor-α (TNF-α) also contribute to regulation of the acute-phase response [Gruys et al., 2005].

    The source of IL-6 is likewise heterogeneous. Activated monocytes and macrophages can produce IL-6, but so can a range of nonimmune and stromal cell types, including fibroblasts, vascular endothelial cells, and adipocytes [Pedersen et al., 2001; Hirano, 2021]. The liver therefore receives IL-6 as part of a broader intercellular inflammatory network rather than as a signal originating from a single cell population.

    This distinction is important mechanistically. The hepatic acute-phase response is best understood as one downstream arm of systemic inflammatory communication, with IL-6 serving as a major—but not exclusive—signal that links inflammatory activity to changes in hepatocyte gene expression.


    The Acute-Phase Output Is Broader Than CRP

    Positive acute-phase proteins form a coordinated output

    The liver is a major effector organ of the acute-phase response. Following IL-6 stimulation, hepatocytes increase production of multiple acute-phase proteins, including CRP, SAA, and haptoglobin [Heinrich et al., 1990; Schmidt-Arras and Rose-John, 2016].

    These proteins should not be treated as interchangeable readouts. They differ substantially in biochemical structure and biological function.

    CRP binds phosphocholine-containing structures on some microbial surfaces and phospholipids exposed on apoptotic cells. Through interactions that include activation of the classical complement pathway and opsonization, CRP can facilitate clearance by macrophages and other components of innate immunity [Black et al., 2004; Gershov et al., 2000].

    SAA follows a different biological trajectory. During the acute phase, SAA becomes a major apolipoprotein component of HDL and is thought to alter HDL particle composition and function, thereby affecting lipid transport, including reverse cholesterol transport. In experimental systems, SAA also displays chemotactic activity toward monocytes and neutrophils and may contribute to their recruitment to inflammatory sites [Uhlar and Whitehead, 1999; Badolato et al., 1994; Sack, 2018].

    Haptoglobin provides another distinct example. It binds free hemoglobin in plasma with high affinity, forming a stable haptoglobin–hemoglobin complex. By limiting oxidative reactions driven by extracellular hemoglobin, this system can reduce vascular and tissue injury [Andersen et al., 2012; Cooper et al., 2013].

    Thus, a rise in CRP is only one component of an IL-6-responsive hepatic program. The broader output consists of proteins with different roles in microbial recognition, complement-associated defense, lipid transport, inflammatory-cell recruitment, and protection from oxidative injury.

    Evidence from primary human hepatocytes

    Studies using primary human hepatocyte cultures provided early experimental support for the central role of IL-6 in the regulation of positive acute-phase proteins. These studies indicated that IL-6 regulates the production of multiple positive acute-phase proteins and that at least part of this regulation occurs before translation [Castell et al., 1990].

    This observation is mechanistically important because it moves the analysis upstream from circulating protein concentrations to the regulation of gene expression. The next question is therefore how the extracellular IL-6 signal reaches the transcriptional machinery of the hepatocyte.


    Two Receptor Routes into gp130 Signaling

    Classic signaling through membrane-bound IL-6R

    In classic signaling, IL-6 first binds the membrane-bound IL-6 receptor (mIL-6R) on cells that express this receptor. The IL-6–mIL-6R complex then recruits two gp130 molecules, leading to formation of a hexameric signaling complex containing two molecules each of IL-6, mIL-6R, and gp130 [Rose-John, 2018; Boulanger et al., 2003].

    Formation of this receptor complex initiates intracellular signaling centered on Janus kinases (JAKs) and STAT3. In hepatocytes, this classic receptor architecture provides a direct route through which circulating IL-6 can be translated into transcriptional responses.

    Trans-signaling expands the responsive cell repertoire

    IL-6 can also signal through a second route. In trans-signaling, IL-6 binds the soluble IL-6 receptor (sIL-6R), and the resulting IL-6–sIL-6R complex engages gp130 on the surface of target cells. Because gp130 is more widely expressed than mIL-6R, this mechanism allows IL-6 to act on gp130-expressing cells that do not themselves express membrane-bound IL-6R [Scheller et al., 2011].

    Trans-signaling has been implicated in the maintenance of chronic inflammatory states and, in some experimental systems, in tumor formation and progression, including models of inflammation-associated colorectal carcinogenesis [Scheller et al., 2006; Rose-John, 2012].

    These observations do not establish a universal division in which classic signaling is physiological and trans-signaling is pathological. Rather, they show that IL-6 receptor biology expands the cellular contexts in which IL-6 can act. The functional consequences of this distinction become particularly important when selective inhibition of trans-signaling is considered in Part 3.


    From gp130 Activation to STAT3-Dependent Transcription

    JAK activation and STAT3 Tyr705 phosphorylation

    In hepatocytes, once the hexameric IL-6–mIL-6R–gp130 complex described above has formed, gp130-associated JAKs are activated and phosphorylate tyrosine residues within the intracellular region of gp130. STAT3 is then recruited and phosphorylated at Tyr705 [Heinrich et al., 2003].

    Phosphorylated STAT3 dimerizes and translocates to the nucleus. There, it participates in regulation of acute-phase genes by binding regulatory DNA regions and by functioning within transcriptional complexes that can include factors such as NF-κB and C/EBPβ [Heinrich et al., 2003; Zhang et al., 1995; Hagihara et al., 2005; Ngwa et al., 2022].

    This transcriptional layer is important for CRP, SAA, fibrinogen, and other IL-6-responsive genes. STAT3 is therefore central to hepatic acute-phase transcription, but it is not a solitary molecular switch. Its activity occurs within a broader transcriptional environment in which other transcription factors and regulatory cofactors contribute to gene-specific responses.

    That distinction becomes the starting point for Part 2, where the analysis moves beyond STAT3 phosphorylation to post-translational modification, coactivator recruitment, chromatin accessibility, and DNA methylation.

    Scientific schematic showing inflammatory triggers and IL-6-producing cells feeding hepatocyte IL-6R/gp130–JAK–STAT3 signaling. STAT3 drives acute-phase gene transcription and production of CRP, SAA, and haptoglobin, while SOCS3 provides negative feedback. A separate inset shows trans-signaling through soluble IL-6R.
    Figure 1. IL-6 signaling in the hepatic acute-phase response.
    Inflammatory stimuli induce IL-6 production from immune and nonimmune cell populations. In hepatocytes, classic signaling through membrane-bound IL-6R and gp130 activates JAK–STAT3 signaling and acute-phase gene transcription, while STAT3-induced SOCS3 provides negative feedback. Trans-signaling through soluble IL-6R expands the range of gp130-expressing responsive cells. CRP, SAA, and haptoglobin are shown as representative outputs of the broader hepatic acute-phase program. Conceptual schematic; not to scale.

    Abbreviations: mIL-6R, membrane-bound IL-6 receptor; sIL-6R, soluble IL-6 receptor; gp130, signal-transducing receptor subunit; CRP, C-reactive protein; SAA, serum amyloid A; SOCS3, suppressor of cytokine signaling 3.


    SOCS3 Closes the Signaling Loop

    STAT3 induces its own negative regulator

    A signaling pathway that induces an acute inflammatory program also requires mechanisms that constrain its persistence. One of the principal negative-feedback systems in IL-6 signaling is built directly into the JAK–STAT3 pathway.

    Activated STAT3 induces transcription of suppressor of cytokine signaling 3 (SOCS3). Newly produced SOCS3 binds phosphorylated Tyr759 within the intracellular region of gp130 and also directly inhibits the kinase activity of receptor-associated JAKs [Matsuda, 2023; Lehmann et al., 2003; Babon et al., 2012].

    The pathway therefore contains an autoregulatory loop:

    IL-6 signaling activates STAT3; activated STAT3 induces SOCS3; SOCS3 then suppresses further signaling through the same receptor-associated machinery.

    Negative feedback limits signal persistence

    SOCS3-dependent autoregulation is one of the major negative-feedback mechanisms that restrict excessive or sustained IL-6 signaling [Yoshimura, 2009; Croker et al., 2003].

    This feedback architecture helps explain why the acute-phase response cannot be understood solely in terms of signal initiation. Its biological behavior also depends on how strongly and how long intracellular signaling persists.

    At the same time, SOCS3 is not the only regulatory layer. The magnitude and context of IL-6-responsive transcription also depend on the molecular state of STAT3 and on gene- and cell-specific transcriptional and chromatin environments. Those layers are the focus of Part 2.


    Conclusion

    The rise of CRP during inflammation is the visible end point of a multilevel signaling process. IL-6 is produced by diverse immune and nonimmune cells, reaches the liver as part of a systemic inflammatory network, and activates hepatocyte signaling through IL-6R and gp130. JAK activation and STAT3 phosphorylation then connect receptor engagement to acute-phase gene transcription, while SOCS3 feeds back onto the same pathway to limit signal persistence.

    CRP is therefore best understood as one output of a broader hepatic acute-phase program that also includes SAA, haptoglobin, and other proteins with distinct biological functions. The pathway cannot be reduced to a single linear equation in which IL-6 simply “becomes CRP.”

    Part 2 moves one level deeper into transcriptional control: how STAT3 modification, p300/CBP, chromatin remodeling, and DNA methylation can alter IL-6-responsive gene regulation in different experimental contexts.

    The molecular relationships discussed here describe general acute-phase biology. They do not provide a basis for interpreting an individual CRP value, determining the cause of inflammation in a particular person, or making diagnostic or treatment decisions.


    Medical Disclaimer

    This article provides general scientific and medical information. It is not intended to interpret individual laboratory results or to support diagnosis, treatment selection, dosing, treatment modification, or treatment discontinuation.


    Production Note

    Figures were created with AI assistance and reviewed by the author for scientific accuracy and clarity.


    Related Articles


    Work With Rin Kamo

    For science writing, biomedical content development, literature research, or scientific editing inquiries, see “Work With Rin Kamo: Science Writing & Biomedical Content Support.”


    References

    Kishimoto T. IL-6: from laboratory to bedside. Clin Rev Allergy Immunol. 2005;28(3):177-186. doi:10.1385/CRIAI:28:3:177. PMID:16129902.
    Rose-John S. Interleukin-6 family cytokines. Cold Spring Harb Perspect Biol. 2018;10(2):a028415. doi:10.1101/cshperspect.a028415. PMID:28620096; PMCID:PMC5793756.

    Hunter CA, Jones SA. IL-6 as a keystone cytokine in health and disease. Nat Immunol. 2015;16(5):448-457. PMID: 25898198. Available from: https://pubmed.ncbi.nlm.nih.gov/25898198/

    Garbers C, Heink S, Korn T, Rose-John S. Interleukin-6: designing specific therapeutics for a complex cytokine. Nat Rev Drug Discov. 2018;17(6):395-412. PMID: 29725131. Available from: https://pubmed.ncbi.nlm.nih.gov/29725131/

    Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol. 2014;6(10):a016295. PMID: 25190079. Available from: https://pubmed.ncbi.nlm.nih.gov/25190079/

    Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340(6):448-454. doi:10.1056/NEJM199902113400607. PMID:9971870.

    Steel DM, Whitehead AS. The major acute phase reactants: C-reactive protein, serum amyloid P component and serum amyloid A protein. Immunol Today. 1994;15(2):81-88. doi:10.1016/0167-5699(94)90138-4. PMID:8155266.

    Gruys E, Toussaint MJM, Niewold TA, Koopmans SJ. Acute phase reaction and acute phase proteins. J Zhejiang Univ Sci B. 2005;6(11):1045–1056. doi:10.1631/jzus.2005.B1045. PMID:16252337; PMCID:PMC1390650.

    Mantovani A, Garlanda C. Humoral innate immunity and acute-phase proteins. N Engl J Med. 2023;388(5):439–452. doi:10.1056/NEJMra2206346. PMID:36724330; PMCID:PMC9912245.

    Pedersen BK, Steensberg A, Schjerling P. Muscle-derived interleukin-6: possible biological effects. J Physiol. 2001;536(Pt 2):329–337. PMID:11600669; PMCID:PMC2278876.

    Hirano T. IL-6 in inflammation, autoimmunity and cancer. Int Immunol. 2021;33(3):127–148. doi:10.1093/intimm/dxaa078. PMID:33337480; PMCID:PMC7799025.

    Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochem J. 1990;265(3):621–636. doi:10.1042/bj2650621. PMID:1689567; PMCID:PMC1133681.

    Schmidt-Arras D, Rose-John S. IL-6 pathway in the liver: from physiopathology to therapy. J Hepatol. 2016;64(6):1403–1415. doi:10.1016/j.jhep.2016.02.004. PMID:26867490.

    Black S, Kushner I, Samols D. C-reactive protein. J Biol Chem. 2004;279(47):48487–48490. doi:10.1074/jbc.R400025200. PMID:15337754.

    Gershov D, Kim S, Brot N, Elkon KB. C-reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an antiinflammatory innate immune response: implications for systemic autoimmunity. J Exp Med. 2000;192(9):1353–1364. doi:10.1084/jem.192.9.1353. PMID:11067883; PMCID:PMC2193350.

    Uhlar CM, Whitehead AS. Serum amyloid A, the major vertebrate acute-phase reactant. Eur J Biochem. 1999;265(2):501–523. doi:10.1046/j.1432-1327.1999.00657.x. PMID:10504381.

    Badolato R, Wang JM, Murphy WJ, Lloyd AR, Michiel DF, Bausserman LL, et al. Serum amyloid A is a chemoattractant: induction of migration, adhesion, and tissue infiltration of monocytes and polymorphonuclear leukocytes. J Exp Med. 1994;180(1):203–209. doi:10.1084/jem.180.1.203. PMID:7516407; PMCID:PMC2191543.

    Sack GH Jr. Serum amyloid A—a review. Mol Med. 2018;24(1):46. doi:10.1186/s10020-018-0047-0. PMID:30165816; PMCID:PMC6117975.

    Andersen CBF, Torvund-Jensen M, Nielsen MJ, de Oliveira CLP, Hersleth HP, Andersen NH, et al. Structure of the haptoglobin-haemoglobin complex. Nature. 2012;489(7416):456–459. doi:10.1038/nature11369. PMID:22922649.

    Cooper CE, Schaer DJ, Buehler PW, Wilson MT, Reeder BJ, Silkstone G, et al. Haptoglobin binding stabilizes hemoglobin ferryl iron and the globin radical on tyrosine β145. Antioxid Redox Signal. 2013;18(17):2264–2273. doi:10.1089/ars.2012.4547. PMID:22702311; PMCID:PMC3638561.

    Castell JV, Gómez-Lechón MJ, David M, et al. Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology. 1990;12(5):1179-1186. PMID: 1699862. Available from: https://pubmed.ncbi.nlm.nih.gov/1699862/

    Boulanger MJ, Chow DC, Brevnova EE, Garcia KC. Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp130 complex. Science. 2003;300(5628):2101–2104. doi:10.1126/science.1083901. PMID:12829785.

    Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta. 2011;1813(5):878–888. doi:10.1016/j.bbamcr.2011.01.034. PMID:21296109.

    Scheller J, Ohnesorge N, Rose-John S. Interleukin-6 trans-signalling in chronic inflammation and cancer. Scand J Immunol. 2006;63(5):321–329. doi:10.1111/j.1365-3083.2006.01750.x. PMID:16640655.

    Rose-John S. IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int J Biol Sci. 2012;8(9):1237–1247. doi:10.7150/ijbs.4989. PMID:23136552; PMCID:PMC3491447.

    Heinrich PC, Behrmann I, Haan S, Hermanns HM, Müller-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J. 2003;374(Pt 1):1–20. doi:10.1042/BJ20030407. PMID:12773095; PMCID:PMC1223585.

    Zhang Z, Fuentes NL, Fuller GM. Characterization of the IL-6 responsive elements in the gamma fibrinogen gene promoter. J Biol Chem. 1995;270(41):24287–24291. doi:10.1074/jbc.270.41.24287. PMID:7592638.

    Hagihara K, Nishikawa T, Sugamata Y, Song J, Isobe T, Taga T, Yoshizaki K. Essential role of STAT3 in cytokine-driven NF-kappaB-mediated serum amyloid A gene expression. Genes Cells. 2005;10(11):1051–1063. doi:10.1111/j.1365-2443.2005.00900.x. PMID:16236134.

    Ngwa DN, Pathak A, Agrawal A. IL-6 regulates induction of C-reactive protein gene expression by activating STAT3 isoforms. Mol Immunol. 2022;146:50–56. doi:10.1016/j.molimm.2022.04.003. PMID:35430542; PMCID:PMC9811655.

    Matsuda T. The physiological and pathophysiological role of IL-6/STAT3-mediated signal transduction and STAT3 binding partners in therapeutic applications. Biol Pharm Bull. 2023;46(3):364–378. doi:10.1248/bpb.b22-00887. PMID:36858565.

    Lehmann U, Schmitz J, Weissenbach M, Sobota RM, Hortner M, Friederichs K, et al. SHP2 and SOCS3 contribute to Tyr-759-dependent attenuation of interleukin-6 signaling through gp130. J Biol Chem. 2003;278(1):661–671. doi:10.1074/jbc.M210552200. PMID:12403768.

    Babon JJ, Kershaw NJ, Murphy JM, Varghese LN, Laktyushin A, Young SN, Lucet IS, Norton RS, Nicola NA. Suppression of cytokine signaling by SOCS3: characterization of the mode of inhibition and the basis of its specificity. Immunity. 2012;36(2):239–250. doi:10.1016/j.immuni.2011.12.015. PMID:22342841; PMCID:PMC3299805.

    Yoshimura A. Regulation of cytokine signaling by the SOCS and Spred family proteins. Keio J Med. 2009;58(2):73–83. doi:10.2302/kjm.58.73. PMID:19597303.

    Croker BA, Krebs DL, Zhang JG, Wormald S, Willson TA, Stanley EG, et al. SOCS3 negatively regulates IL-6 signaling in vivo. Nat Immunol. 2003;4(6):540–545. doi:10.1038/ni931. PMID:12754505.


    #IL-6 #CRP #acute-phase response #JAK-STAT3 #SOCS3

     
     
    賀茂 琳(Kamo Rin)|医学博士/免疫・がん・分子生物学 最新のPubMed論文を基盤に、IL-6を中心とするサイトカイン研究を“高頻度アップデート型”で解説しています。 専門性を保ちつつ、医療者・研究者・学生が実務で使える“理解の手がかり”を届けたいです。

    あなたへのおすすめ